Review. Clinical pharmacokinetics of bortezomib.
This review presents the clinical pharmacokinetics of bortezomib. Aspects regarding metabolism, pharmacodynamics and drug interactions are also discussed.
Levêque
Dominique
D
Hôpital de Hautepierre, Pharmacie, 67000 Strasbourg, France. dominique.leveque@chru-strasbourg.fr
Carvalho
Marie Christine Monteiro
MC
Maloisel
Frederic
F
D000970:Antineoplastic Agents / Q000493:pharmacokinetics* / Q000627:therapeutic use / Q000633:toxicity; D001897:Boronic Acids / Q000493:pharmacokinetics* / Q000627:therapeutic use / Q000633:toxicity; D000069286:Bortezomib; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D007668:Kidney / Q000378:metabolism / Q000473:pathology; D007700:Kinetics; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D009101:Multiple Myeloma / Q000188:drug therapy*; D011719:Pyrazines / Q000493:pharmacokinetics* / Q000627:therapeutic use / Q000633:toxicity
D000970:Antineoplastic Agents; D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib